Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.

Details

Language :

English

ISSN :

0732183X

Volume :

41

Issue :

3

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

161326077

Full Text :

https://doi.org/10.1200/JCO.21.02815